.jpg){kind=tracking}
.jpg){kind=tracking}
The first World Food Safety Day was held on June 7 with deputy commissioner for food policy and response Frank Yiannas representing the Food and Drug Administration.
The National Cannabis Industry Association (NCIA) says the Federal Drug Administration (FDA) should take immediate steps to approve non-psychoactive cannabidiol components such as CBD for general use.
.jpg){kind=tracking}
At the U.S. Food and Drug Administration, increasing our scientific knowledge and capabilities is a cornerstone to ensuring the safety of the foods that Americans consume.
Recent FDA hearing about CBD products emphasises the need for solid Real-Word Evidence Data
North Carolina House Bill 934, which passed unanimously 114-0, was sent to the State Senate where it currently is in committee.
.jpg){kind=tracking}
On May 31, NuLeaf Naturals representative Crystal Guess was one of 140 individuals to testify in a groundbreaking public meeting called by the Food and Drug Administration (FDA).
.jpg){kind=tracking}
Investigational drug pretomanid, developed by non-profit TB Alliance, is under regulatory review for treatment of extensively drug-resistant tuberculosis and treatment-intolerant or non-responsive multidrug-resistant tuberculosis as part of a new investigational regimenthat includes bedaquiline and linezolid
.jpg)
U.S. District Judge Ursula Ungaro of the Southern District of Florida granted the government’s motion for summary judgment against US Stem Cell Clinic LLC, of Weston, Florida, and US Stem Cell Inc., of Sunrise, Florida, and their Chief Scientific Officer Kristin Comella, Ph.D.
Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United Statesthat launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that Dr. Stuart Titus, the Company's Chief Executive Officer, was featured in several national and international news publications about his speaking engagement at the U.S. Food and Drug Administration (FDA) Hearing on cannabis and cannabidiol (CBD) on Friday, May 31, 2019.
NuTek Food Science, LLC, a company that helps create great-tasting and affordable foods to enhance global health and wellness, announced that it is withdrawing its widely supported and highly publicized citizen petition concerning potassium salt that was filed with the FDA in 2016.
The opioid tragedy has become one of the defining public health crises of modern times.
In a safety communication released last week, the Food and Drug Administration warned against unapproved and unauthorized devices for diabetes.
This week, Eli Adashi, Rohit Rajan, and Glenn Cohen will have another paper published in Science that says the FDA is being undermined because of politically motivated congressional legislators, especially recently.
U.S. District Judge Virginia M. Kendall for the Northern District of Illinois entered a consent decree of permanent injunction between the United States and PharMedium Services, LLC, headquartered in Lake Forest, Ill., as well as Scott Aladeen, the company’s president, and Warren Horton, vice president for Quality and Research and Development.
U.S. District Judge Keith P. Ellison for the Southern District of Texas signed and entered a consent decree of permanent injunction, ordering a Texas-based company and its owners to stop producing compounded drugs intended to be sterile until the company complies with the Federal Food, Drug, and Cosmetic Act (FD&C Act) and other requirements.
.jpg)
Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, announced today that the Company's CEO, Dr. Stuart Titus, has been chosen as one of 65 speakers to present oral comments at the U.S. Food & Drug Administration (FDA)'s upcoming public hearing discussing scientific data and information about products containing cannabis-derived compounds.
Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), provided an update on its application for FDA clearance and addressed a recent anonymous article published on SeekingAlpha.com.